NHS England Offers New Drug Treatment to Prevent Blindness in Premature Babies

This treatment is for babies who are at risk of developing retinopathy of prematurity (ROP), which can occur when there is abnormal blood-vessel growth in the back of the eye.

The drug can block the action of vascular endothelial growth factor, which promotes the growth of new blood vessels.

The treatment is an alternative to laser therapy, which is not always suitable for tiny babies.

All premature and low-birth-weight babies are screened for ROP, with eye tests, and up to one in 20 may require treatment to avoid damage that can lead to sight loss.

The drug treatment is given through injections into the eye and is expected to benefit around 20 babies a year in England.